News | Ultrasound Imaging | February 27, 2020

Emagine Solutions Technology Receives FDA 510(k) Clearance for VistaScan Mobile Ultrasound

Emagine Solutions Technology's VistaScan portable ultrasound enables doctors to enhance patient care. Clinicians can diagnose in moments, saving time and lives at a fraction of the cost of a cart ultrasound machine

Emagine Solutions Technology's VistaScan portable ultrasound enables doctors to enhance patient care. Clinicians can diagnose in moments, saving time and lives at a fraction of the cost of a cart ultrasound machine. Photo credit: Tech Parks Arizona

February 27, 2020 — Emagine Solutions Technology, an award-winning medical software device company located in Tucson, announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to market its VistaScan mobile ultrasound platform. 

The VistaScan platform transforms a clinician's cell phone or tablet into a portable ultrasound solution. The system consists of compatible FDA cleared ultrasound probes that interface with the VistaScan software application. VistaScan's proprietary patent-pending Dynamic Precise Point Measuring System enables a healthcare provider to maximize the accuracy of a mobile device's touchscreen to make highly precise, to-the-pixel measurements on the ultrasound image, thereby increasing diagnostic performance and speed.  

"The velocity and complexity of modern medicine is becoming overwhelming, and putting the power of ultrasound into the pockets of clinicians so they can use it for real time diagnosis right at the bedside is liberating and transformative," commented Dr. Berndt Schmit, Section Chief of Emergency Radiology at Banner University Medical Center at the University of Arizona and President of Humanitarian Radiology Development Corps.

Emagine Solutions Technology has already won a number of accolades prior to its launch of VistaScan, including grant funding from National Science Foundation and Roddenberry Foundation, the Flinn Foundation Bioscience Entrepreneurship award, National AURP Award, and was a Governor's Celebration of Innovation Finalist this year. The company is also a Pipeline Angels investment portfolio company. 

"Receiving FDA clearance is excellent validation of our technology and demonstrates the role handheld ultrasound will play in enhancing patient care," commented Courtney Williams, co-founder and CEO of Emagine Solutions Technology.

Emagine Solutions Technology is a certified Women's Business Enterprise by the Women's Business Enterprise Council and was founded to expand access to diagnostic ultrasound technology, particularly in the area of women's health. 

For more information: www.vistascan.co

Related Content

An example of cardiac ultrasound longitudinal strain measurements on the Epsilon EchoInsight software. This can be used to assess cardiotoxicity from chemotherapy agents. 

An example of cardiac ultrasound longitudinal strain measurements on the Epsilon EchoInsight software. This can be used to assess cardiotoxicity from chemotherapy agents. 

News | Cardio-oncology | February 25, 2021
February 25, 2020 — Results of a multi-centre, international, clinical trial co-led by Peter Munk Cardiac Centre (PMC
Advanced technologies and applications such as point-of-care, pediatrics, dry-magnets, compact MRI and fusion imaging are driving global market
News | Magnetic Resonance Imaging (MRI) | February 24, 2021
February 24, 2021 — Frost & Sullivan's recent analysis, Technological Advancements and Emerging Applications in t
55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
Detroit-based magnetic resonance imaging (MRI) technology company SpinTech, Inc. has acquired medical-imaging research and technology developer Magnetic Resonance Innovations, Inc. (MR Innovations).
News | Magnetic Resonance Imaging (MRI) | February 24, 2021
February 24, 2021 — Detroit-based magnetic resonance...
Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer

Image courtesy of UCLA Health

News | PET-CT | February 23, 2021
February 23, 2021 — A...
Axial FLAIR MR image shows T2 prolongation in bilateral middle cerebellar peduncles (arrows). Findings were associated with restricted diffusion and areas of T1 hypointense signal without enhancement or abnormal susceptibility. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Axial FLAIR MR image shows T2 prolongation in bilateral middle cerebellar peduncles (arrows). Findings were associated with restricted diffusion and areas of T1 hypointense signal without enhancement or abnormal susceptibility. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | February 22, 2021
February 22, 2021 — According to an...
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne
Dr Sahar Saleem placing the mummy in the CT scanner

Dr. Sahar Saleem placing the mummy in the CT scanner. Image courtesy of Sahar Saleem

News | Computed Tomography (CT) | February 22, 2021
February 22, 2021 — Modern medical technology is helping scholars tell a more nuanced story about the fate of an anci
 Enterprise imaging systems provider Intelerad Medical Systems announced it has acquired Lumedx, a leading provider of healthcare analytics and cardiovascular information systems (CVIS). 
News | Enterprise Imaging | February 18, 2021
February 18, 2021 – Enterprise imaging systems provider Intelerad Medical Systems announced it has acquired...